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A commentary on
The international society for bipolar dis-
orders (ISBD) task force report on anti-
depressant use in bipolar disorders
by Pacchiarotti I, Bond DJ, Baldessarini RJ,
Nolen WA, Grunze H, Licht RW, et al. Am J
Psychiatry (2013) 170(11):1249–62.
Antidepressants are still widely used in the
treatment for bipolar disorder (BD), but
evidence do not support their extensive
use during depressive episodes. Recently,
an important systematic review was pub-
lished after an extensive literature search
on the use of antidepressants in bipolar
depression (1). Based on the conclusions, in
spite of a considerable number of clinical
studies (more than 37 so far) and meta-
analyses currently available, the authors
did not make broad statements endorsing
antidepressant use in BD, but acknowledge
that individual bipolar patients may bene-
fit from these agents. Other studies showed
similar results (2).
These publications also call attention
to a wide range of methodological issues
and discrepancies as well as to heteroge-
neous statistical approaches and conclu-
sions. Also, studies have emphasized other
limitations (2) including small samples,
co-treatments, lack of adequate controls,
and varied design, and therefore, current
clinical evidence seems still inconclusive.
Thus, the first generation of stud-
ies has not provided consistent clinical
answers to ensure more generalizable con-
clusions and guidelines for clinicians. They
focused primarily in answering two simple
questions: first, testing “yes or no” for the
use of antidepressants regarding efficacy
and safety (switch risk) in bipolar depres-
sion. This linear paradigm still does not
help to guide clinicians’ therapeutic deci-
sion. The second question aimed to address
what agent (or class) would be more effec-
tive and safer in bipolar depression. These
two main aspects still remain not fully
elucidated and additional questions have
arisen, described next. Also, the role of
BD diagnosis (bipolar I or II), family his-
tory and the risk of cycle acceleration, sui-
cidality, mixed episodes/rapid cycling as
associated outcomes did not provide yet
consistent guidance. These variables were
evaluated as secondary analyses and did
not present standardized definitions (e.g.,
switch process and cycle acceleration). In
the same perspective, even though it is clear
that antidepressant monotherapy is con-
traindicated in bipolar depression, some
large studies used this approach to compare
with new agents (e.g., EMBOLDEN II).
Thus, this is an area where future stud-
ies critically require translational approach
for the next generation of clinical trials
(3). Only few trials with antidepressants
in bipolar depression have systematically
evaluated the potential clinical usefulness
of biomarkers that may predict antidepres-
sant response in BD and even less have
thoroughly assessed the potential biolog-
ical basis of switch risk. Most of the stud-
ies also have limitations including small
samples, co-treatments, lack of adequate
controls, and varied design.
The identification of neurobiologi-
cal substrates able to minimize sample
heterogeneity may also help to identify
potential enriched samples for further con-
firmatory studies with different classes of
antidepressants would be a critical step
forward. This may also provide evidence
to support the use of antidepressants in
specific subgroups and guide clinical deci-
sion in the personalized treatment para-
digm. At the same time, the development
of standardized conceptual definitions is
essential to perform neurobiological stud-
ies and may be added to the evaluation of
diverse constructs and dimensions across
neurobiological systems.
In the same context, the next genera-
tion of proof of concept studies is also
expected to provide information on which
clinical and neurobiological variables are
associated with a subgroup that will likely
respond to a specific antidepressant and
address key questions including optimal
duration of antidepressant treatment and
presence (or not) of a dose- and/or time-
dependent regulation of mood elevation
using adequate methodology (e.g., more
frequent rating scales, standard dose esca-
lation design). These approaches may also
help to define the lowest effective dose
for the shortest time necessary for sus-
tained remission. Future studies would
also benefit from dimensional approaches
and evaluation of new targets such as the
glutamatergic system.
Finally, it is also critical to better under-
stand this complex and non-linear inter-
action, the study of specific domains such
as early improvement, short and long-term
response, cognition, role of compliance,
duration of use, and dosage/response
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curve. These are important variables to
be considered integrated with biomark-
ers such as predictors of response and
surrogate outcomes. The next generation
of studies is also expected to evaluate a
broader risk–benefit equation, integrating
generalizable data to discoveries on per-
sonalized treatments for those who need
it most.
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